In privately insured adults over age 50, abaloparatide use remained below 2% of osteoporosis medication users throughout the study period.
In plain wordsAmong privately insured adults over age 50 receiving osteoporosis medication, abaloparatide use remained below 2% throughout the study period.
- Peptide
- Abaloparatide (Tymlos)
- Outcome
- Not applicableAbaloparatide prescribing share
- Study
n: not reported in source
- Outcome group
- Patterns of use · Whole body
Measurements
- Medication use
- < 2%
- all-user cohort
Source sentences
Use of teriparatide, abaloparatide, and romosozumab remained less than 2% throughout the study period.
2 context sentences(design, population, supporting numbers)
Using claims data from the Clinformatics Data Mart (Optum, Inc.), we determined the number of enrolled individuals over age 50 who were prescribed any osteoporosis medication during each quarter between January 1, 2009 and March 31, 2020.
Of all individuals receiving therapy, we then calculated the percent receiving each medication.
In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).